{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-013050","form_type":"8-K","ticker":"CGC","cik":"0001737927","company_name":"Canopy Growth Corp","filed_at":"2024-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.349766+00:00","generated_at":"2026-06-06T04:55:23.518089+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Canopy Growth Q3 FY2024 revenue $78.5M; adjusted EBITDA loss narrows 82% to $9M","bullets":["Net revenue $78.5M, down 7% YoY; net loss from continuing operations $230.3M.","Adjusted EBITDA loss $9.0M, improving 82% from $50M loss in Q3 FY2023.","Canada medical cannabis revenue record $15.6M (+11% YoY); Canada B2B adult-use revenue up 9%.","Cash and short-term investments $186M; debt reduced by $69M during quarter.","Canopy USA special meeting set for April 12, 2024; board appoints two new directors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-013050","json":"https://secwatch.observer/filing/0000950170-24-013050.json","markdown":"https://secwatch.observer/filing/0000950170-24-013050.md","text":"https://secwatch.observer/filing/0000950170-24-013050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737927/000095017024013050/0000950170-24-013050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737927/000095017024013050/cgc-20240209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T04:55:23.518089+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"81f4c4898ba2d197886654ccdc134c52fda5ec79","claim":"Canopy Growth Corp reported fiscal third quarter ended December 31, 2023 results: revenue $79MM, net income $(230.3). Guidance reaffirmed.","evidence_excerpt":"divestiture of the Canada national retail business in Q3 FY2023, Q3 FY2024 consolidated net revenue grew by 6% year-over-year. Delivered Q3 FY2024 consolidated net revenue of $79MM representing a decline of 7% year-over-year. • Rest-of-World cannabis revenue in Q3 FY2024 increased 81% year-over-year, led by continued strong growth in Australia, return to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737927/000095017024013050/0000950170-24-013050-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal third quarter ended December 31, 2023"},{"label":"Revenue","value":"$79MM"},{"label":"Net income","value":"$(230.3)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}